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S_ry The efficacy of cisplatin [cis-diamminedichloroplatinum (IT); DDP] is hampered by acquired or de
novo resistance of malignant to its cytotoxic effects. We have previously reported that cisplatin resistance
paralklis glutathione S-transferase (GST) activity in several human small-cell lung cancer ce lines. In the
presently described studies, we used sala7ine, an inhibitor ofGSTs, to evahlate the relative role ofGSTs
in mediating cisplatin resistan in two human small-cell lung cancer cell lines, NCI H-69 and H-24%. The
H-69 cell line, which contained relatively higher GST activity than the H-2496 cell line (317 ± 7 vs
9 ± 1 mU mg-' protein respectively), also displayed a greater degree of cisplatin resistance (IC5o values of
25.0 ± 3.9 vs 4.5 ± 1.0 pi respecively). Western blot and Northern blot analyses ofpurified GSTs revealed the
ecpression of only the s-dass GST in both cell ines. Sulphasalazine inhibited the purified GSTs (IC5u of
10 LM for H-69 and 12fm for H-2496) from both ines in a competitive manner with smilar K vahles (6.5
and 7.9 gM for the H-69 and H-2496 cell lines e). Cytotoxicity studies revealed that sulphasalazne
increased the cytotoxicity ofcisplatin towards both cel lines. Isobologram analysis showed that lhsalazi
synergistically enhanced the cytotoxicity of cisplatin towards both cell lines, the maginitude of synergy being
remarkably higher in H-69 cells than in H-2496 cells. Our saudies indicate that clnically achievable concentra-
tions of s salazine may be useful in modulating cisplatin resistance in malignancies with increased
GST-x content.
Cisplatin [cis-diamminedichloroplatinum (II); DDP] is an
electrophilic platinum coordinate compound which causes
DNA damage by forming platinum-DNA coordination
complexes (Zwelling & Kohn, 1980). It is one of the most
effective antineoplastic agents clinically used against human
small-cell lung cancer (SCLC) (Aisner, 1988). However, its
clinical efficacy as an antineoplastic agent is curtailed in
many cancers owing to inherent or acquired resistance to its
cytotoxicity (Loehrer & Einhorn, 1984). Attempts are cur-
rently under way to improve the efficacy of DDP by using
non-cytotoxic drugs to defeat cellular defence mechanisms
that participate in mediating resistance to DDP (Timmer-
Bosscha et al., 1992). Cellular defence mechanisms that pro-
tect cells from DDP-induced DNA damage (Kelley &
Rozencweig, 1989; Perez et al., 1990; Tunmer-Bosscha et al.,
1992) can be conceptualised as those that repair DDP-
induced DNA damage (Teicher et al., 1987; Masuda et al.,
1990), those that decrease the accumulation of DDP into the
cell (Teicher et al., 1987; Andrews et al., 1988; Bungo et al.,
1990) or those that increase the capacity of cytoplasmic
defence mechanisms which interfere with the ability of elec-
trophilic toxins, such as DDP, to interact with DNA (Meijer
et al., 1990; Kasahara et al., 1991; Muller et al., 1991).
Glutathione (GSH), the chief intracellular nucleophile, func-
tions as a scavenger of electrophilic toxins, and its cellular
concentrations have been shown to be increased in some
DDP-resistant cell lines (Batist et al., 1986; Meijer et al.,
1990; Mistry et al., 1991). Glutathione S-transferases (GSTs)
are multifunctional cellular enzymes which can detoxify elec-
trophiles by conjugating them with GSH (Jakoby, 1978).
I[creased GST activity has been linked with DDP resistance
(Teicher et al., 1987; Saburi et al., 1989; Miyazaki et al.,
1990; Puchalskci & Fahl, 1990; Sharma et al., 1993). Because
GSTs are susceptible to inhibition by a number of non-
cytotoxic drugs (van Bladeren & van Ommen, 1991), they are
an attractive target for attempts to enhance DDP efficacy
using non-cytotoxic inhibitors, such as ethacrynic acid (a
non-cytotoxic diuretic drug). Ethacrynic acid has been shown
to enhance the cytotoxic effects of certain alkylating agents
(Tew et al., 1988). However, the GST-x isoenzyme, which has
been linked with malignant transformation and with resist-
ance to alkylating agents (Tsuchida & Sato, 1992), has been
suggested to decrease the efficacy ofethacrynic acid in enhan-
cing alkylating agent cytotoxicity (Kuzmich et al., 1992).
Furthermore, ethacrynic acid has been found not to enhance
the cytotoxicity of DDP towards resistant malignant cell lines
(Plumb et al., 1990).
During studies aimed at finding alternative non-cytotoxic
GST inhibitors, we have found that sulphasalazine (SS), a
drug commonly used for the treatment of inflammatory
bowel disorders, is an effective inhibitor of GSTs including
GST-x (Ahmad et al., 1992). We have also studied elec-
trophile defence mechanisms, including GSH levels, and
activities of enzymes which participate in detoxification of
electrophilic toxins, including GSTs, glutathione peroxidase
(GPx), glutathione reductase (GR) and glucose-6phosphate
dehydrogenase (G6PD), and have found that among these
defence mechanisms GST activity correlated best with degree
of DDP resistance in these cell lines (Sharma et al., 1993).
The present studies were designed to test the role of GSTs in
mediating DDP resistance in two human SCLC cell lines,
NCI H-69 and H-2496, in which GST activities parallel DDP
resistance, by studying the effect of SS on their GSTs and
sensitivity to DDP. The inhibitory effects of SS of GST
activity were studied using GSTs purified from these cell
lines. A spectrophotometric cytotoxicity assay (Carmichael et
al., 1987; Twentyman & Luscombe, 1987) which utilises 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MMT) was used in conjunction with isobologram analysis
(Steel & Peckham, 1979) to determine whether SS is able to
enhance the cytotoxicity of DDP in a synergistic manner.
The major GST isoenzyme in both cell lines was found to be
GST-x. SS was found to be a competitive inhibitor of GST-x
at concentrations which can be achieved in human serum
with its conventional doses (Das & Dubin, 1976). SS was
found to enhance the cytotoxicity of DDP in a synergistic
manner in both cell lines, but the degree of synergy was
considerably greater towards the H-69 cell line, which was
relatively more resistant to DDP and which had a higher
GST-x content than the H-2496 cell line. These results sup-
port the results of our previous studies (Sharma et al., 1993)
which have implicated GST-: as a significnt determinant of
DDP resistance and suggest that SS could be clinically used
to enhance the anti-tumour efficacy of DDP in malignant
cells overexpressing GST-w.
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Materiak and methods
Reagents and chemicals
Reagents including SS and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 1-chloro-2,4-dini-
trobenzene (CDNB), 5,5'-dithiobis-2-nitrobenzoic acid
(DTNB), dimethylsulphoxide (DMSO), diethylpyrocar-
bonate, formamide, guanidinium thiocynate and other
reagents were purchased from Sigma (St Louis, MO, USA).
A random primed labelling kit was purchased from Boeh-
ringer-Mannheim (Indianapolis, IN, USA). RadiolabeLled [4-
32P]dCTP (specific activity 6 x 1(9 c.p.m. jig ') was purchased
from DuPont NEN Products (Billerica, MA, USA). Zetabind
nylon membrane was purchased from Cuno Laboratory
(Meridien, CT, USA). DDP was obtained from Bristol
Laboratories (Evansville, IN, USA). Fetal bovine serum
(FBS) was purchased from Intergen Company (Purchase,
NY, USA). Cell culture supplies including RPMI-1640
medium, penicillin-streptomycin (P/S) solution and Dulbec-
co's phosphate-buffered saline (PBS) were purchased from
Gibco Laboratories (Grand Island, NY, USA).
Culture conditions
Two human SCLC cell lines, NCI H-69 and NCI H-2496,
were generous gifts from H. Oie at the National Cancer
Institute, Baltimore, MD, USA. These SCLC cell lines, which
had never been exposed to chemotherapeutic drugs in vitro,
grew in suspension cultures in RPMI-1640 medium contain-
ing 10% FBS and 1% P/S at 37C in a 5% carbon dioxide
atmosphere. Cells were maintained in the log phase of
growth by diluting them 1:3 with medium every 2-3
days.
Non-protein sulphydryl content ofcell lines
Cells growing in log phase were washed with PBS and
homogenate prepared by sonication in 10 mm potassium
phosphate buffer, pH 7.0. Non-protein sulphydryl (NPSH)
content in the acid-soluble fraction of the homogenate was
determined spectrophotometrically using DTNB (Beutler et
al., 1963).
GSTactivity, purification, Western blot analysis andkinetics
ofinhibition by sulphasalazine
GST activity towards CDNB was determined (Habig et al.,
1974) on 28,000g supernatants of the homogenate prepared
as described above. One unit of GST activity was defined as
I ymol of dinitrophenyl-S-glutathione (Dnp-SG,
c0 = 9.6 mM 'cm-') formed per minute at 25C. GSTs
were purified from cell homogenate of both cell lines using
GSH affinity chromatography as used by us previously
(Sharma et al., 1993). Western blot analysis on the purified
GSTs was performed (Towbin et al., 1979) using polyclonal
antibodies specific for the a, 1i and x classes of GST. To
determine a dose-response curve for inhibition of GST,
purified enzyme was incubated with varying concentrations
of SS followed by measurement of initial rate of Dnp-SG
formation spectrophotometrically. Two concentrations of SS
(one above and one below the concentration which caused
50% inhibition of GST activity) were used with varying
concentrations of CDNB to determine initial velocity for
generating double reciprocal plots. V. and K. for CDNB
and nature ofinhibition ofGST by SS were determined from
these plots. Replots of the slopes from the double reciprocal
plots were used to determine &.
Northern blot analysis ofGST RNA expression in cell lines
cDNA probes for the a, p and x class GSTs were prepared
by restriction endonuclease digestion of plasmids containing
cDNA clones of the a-class GST Ha-l (a gift from C.P.D.
Tu, Department of Molecular and Cell Biology, The Pennsyl-
vania State University, University Parkl, USA), the x-class
GST a gift from M. Muramatsu, Department of Biochemis-
try, University of Tokyo, Japan) and the g-class GST (a gift
from I. Listowsky, Department of Biochemistry, Albert Eins-
tein Medical College, New York, USA). The cDNA
fragments were purified by a method utilising low melting
temperature agarose gel eectrophoresis (Falson, 1992). The
probes were labelled by the random-primed labelling method
according to the manufacturer's (Boehringer-Mannim)
recommendations using [a-3PJdCTP, and the unincorporated
nucleotides were removed by filtration through Millipore
Ultra Free MC filter units [10,000 nominal molecular weight
limit (NMWL)]. RNA was isolated from 4 x 10( cells by acid
guanidinium thiocyanate-phenol-chloroform extraction
(Chomoczynski & Sacchi, 1987) and the concentration and
punty were determined spectrophotometrically by measuring
absorbance at 260 and 280 nm. A 25 Ig aliquot of the
isolated RNA from both cell lines was subjected to for-
maldehyde-agarose gel electrophoresis in a 1.2% agarose gel
at 35 V overnight and transblotted to Zetabind nylon memb-
rane. Nylon filters were prehybridised overnight at 5O'C in
hybridisation buffer (0.2 M sodium phosphate pH 7.2, 1%
bovine serum albumin, 7% SDS, I mM EDTA and 15%
formamide) and hybridised in the same buffer with the cor-
responding 32P-labelled DNA probes at 50°C overmight.
Filters were washed once at 50C for 25 min, and twice at
room temperature for 5 min each in washing buffer (40 mM
sodium phosphate pH 7.2, 1 mM EDTA and 1% SDS).
Filters were exposed to Kodak XAR-5 X-ray film at - 80C
using intensifying screens.
Determination ofICsofor cisplatin and SS
A modified MTT cytotoxicity assay similar to that previously
described (Carmichael et al., 1987; Twentyman & Luscombe,
1987) was standardised to determine the numbers of viable
cells after cisplatin and/or SS treatments. Briefly, aliquots
containing approximately 5,000 cells were taken from flasks
containing cells in log phase growth at a density of
3-5 x I0 cells ml-' and inoculated into 96-well plates. The
cells were diluted with medium containing various concentra-
tions of DDP and/or SS. After 72 h, 201AI of MIT
(2mgml-1) was added to each well followed by incubation
for 1 h at 3rC. The cells were centrifuged in Eppendorf
tubes at 28,000 g for 10 min. The supemnatant was discarded
and the pellet thoroughly solubilised in 50 1I of DMSO,
followed by addition of 1 ml of isopropanol. The absorption
of this extract was recorded at 560 nm using a Gilford Re-
sponse spectrophotometer. Surviving cell number was
quantified using a standard curve of cell number versus
absorbance at 560 nm. The IC5 values for DDP and SS were
determined from a plot of percentage surviving cells (com-
pared with control cells) versus drug concentrations. All
cytotoxicity experiments were conducted four times, each
with triplicate determinations, and the average values and
standard deviations were used to construct log survival
curves and isobolograms.
Isobologram analysis
Isobolograms and envelopes of additivity were constructed
according to the previously described method (Steel & Peck-
ham, 1979). Briefly, the IC5o values obtained for DDP and SS
alone were plotted on a Cartesian plane at equal distances
from the origin on the x- and y-axes respectively. The line
connecting these points was designated the theoretical iso-
toxic dose line, or the combination of DDP and SS concen-
trations at which 50%/. ofcells would survive provided the log
survival curves of both drugs were linear. However, this
theoretical isotoxic dose line, which represents simple
additivity of cytotoxicity of both drugs at any combination
of concentrations, may not apply to non-linear log survival
curves of one or both drugs. Since, the survival curve for SS
was not linear, an envelope ofadditivity of DDP and SS was
calculated from the cell survival data as described previously
(Steel & Peckham, 1979). The IC5( values of DDP determined192 S. AWASTHI et al.
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Fuge 1 Western blot analysis of GSTs purified from human SCLC cell lines, H-69 and H-2496, with polyclonal antibodies
specific for GST-oE, -j and -x. In all three panels, lane 1 contained purified antigens as positive controls. Lanes 2 and 3 contained
5 ig of GSH affinity-purified GSTs from the H-69 and H-2496 cell lines respectively.
at several fixed concentrations of SS (below the ICs value of
SS) were plotted against the corresponding concentration of
SS. A curve thus generated and lying below the envelope of
additivity was taken as the evidence of synergy between the
cytotoxic effects of two drugs.
Results and disc
The average NPSH contents of the H-69 and H-2496 cell
lines from three separate determinations were found to be
60.4 ± 5.8 and 44 ± 7.2 nmol mg-' protein respectively. One
hour after exposure to 1 mM SS, average NPSH contents of
the H-69 and H-2496 cell lines from three separate deter-
minations (62.2 ± 6.4 and 41.0 ± 5.8 nmol mg-' protein
respectively) were not significantly altered acutely by
exposure to SS. These results are consistent with a previous
report that SS is not conjugated with GSH (Das & Dubin,
1976) and suggest that any effect of SS on DDP sensitivity is
not caused by SS-induced changes in NPSH. Western blot
analysis of purified GSTs revealed the presence of only the
GST-x isoenzyme in these cell lines (Figure 1). The results of
Northern blot analysis revealed that only GST-c was present
in both cell lines, and GST-a or -j RNA was not detected
(figures not presented). These results were consistent with
previous studies on the composition of GST isoenzymes in
human SCLC cell lines (Miyazaki et al., 1990). The average
GST activity, determined in homogenates of the H-69 and
H-2496 cell lines in three separate experiments (317 ± 7 vs
9 ± 1 mU mg-' protein respectively), indicated that the H-69
cell line contained 34-fold higher GST activity than the H-
2496 cell line (Sharma et al., 1993). SS inhibited GSTs of
both cell lines with 50% inhibition of activity towards
CDNB as seen at 10 and 12 pM for the H-69 and H-2496 cell
lines respectively (Figure 2). SS was found to be a com-
petitive inhibitor of the GSTs isolated from both cell lines,
with KX values of 6.5 and 7.9 9AM for the H-69 and H-2496
cell lines respectively.
An MTT cytotoxicity assay was used to determine the
sensitivity of the SCLC cell lines to DDP and sulphasalazine
alone and in combination. This assay is based on the optical
measurement of a formazan dye which is cleaved from MTT
by mitochondrial dehydrogenase of actively respinng mito-
chondria and has been shown to correlate with results of
colony-forming cytotoxicity assays in SCLC cell lines (Car-
michael et al., 1987). The calibration curve of the MTT
cytotoxicity assay revealed that absorbances at 560 nm were
linear in the range 0.05-1.0 with respect to cell number
determined by counting disaggregated cells in a haemo-
cytometer (data not presented). Using this assay, the H-69
cell line was found to be approximately 6-fold more resistant
to DDP than the H-2496 cell line (average IC50 values from
four separate experiments of 25 ± 3.9 and 4.5 ± 1.0g.M for
the H-69 and H-2496 lines respectively). The log survival
curves for the H-69 and H-2496 cell lines for DDP (Figure
c .
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Fugue 2 Dose-response curve for inhibition of purified GSTs
by sulphasalazine. The percentage inhibition, with respect to
control, of activity of GSTs purified from the H-69 (0) and
H-2496 (0) towards CDNB at each concentration of sulphas-
alazine is plotted against the corresponding sulphasalazine con-
centration. The values presented represent means and standard
deviations from three separate determinations.
3a) and SS alone (Figure 3b) are presented. These survival
curves were linear with respect to DDP concentrations, but
non-linear with respect to SS concentrations, for both cell
lines. On the basis of these results, the use of envelopes of
additivity became necessary for the analysis of synergy in
isobolograms rather than the theoretical isotoxic dose line,
which represented simple additivity of cytotoxicity between
the two drugs. Isobolograms showing the theoretical
envelopes ofadditivity and the actual isotoxic dose curves for
combinations of SS and DDP are shown for the H-69
(Figure 4a) and H-2496 (Figure 4b) cell lines respectively.
The isotoxic dose curves for both cell lines were found to lie
below the theoretical isotoxic dose line, indicating that SS
was able to enhance the cytotoxicity of DDP in a synergistic
manner. The degree of synergy, reflected in the degree of
deviation from the envelope of additivity, was significantly
greater for the more resistant H-69 cell line having higher
GST activity than the H-2496 cell line. Greater synergy
between SS and DDP in the H-69 cell line, which contains
significantly higher GST activity than the DDP-sensitive H-
2496 cell line, suggested that GST may play a prominent role
in mediating DDP resistance. Since GSTs have not been
GST-P GST-t
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Fume 3 Log survival curves of the H-69 (+) and H-2496 (0)
cell lines with respect to (a) cisplatin and (b) salai
concentratin. The results presented are mean and standard
deviations calculated from tripliate determination in four
separate experiments.
shown to catalyse the conjugation of GSH with DDP, fur-
ther studies are required to elucidate the mechanisms through
which GSTs may participate in defence ofcells towards DDP
and define the mechanism of enhancement of DDP cytotox-
icity by SS. In addition to GST inhibition, SS has been
shown to affect the synthesis of leukotrienes and prostaglan-
dins from arachidonic acid contained in plasma membranes
(Tomhamnre et al., 1989), but its effects on protein kinase C
have not been reported. Since inhibitors of protein kinase C
can potentiate DDP cytotoxicity (Timmer-Bosscha et al.,
.Cpq500
o 400 % -c
U) 300
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ICse ofcisplatin
b
Co
X 200
0
u 100
0
0 1 2 3 4
ICs5 ofcisplatin
FM.%e 4 Isobokors of cisplatin and salazine ( )
with the envelopes of additivity (---) for the (a) H-69 and (b)
H-2496 cdl ines The isobogram and envelopes of additivity
were constucted usng the method described by Steel & Peckham
(1979). The values presented represent means and standard devia-
tions from tnpicate determinations of ICSo values in four
separate deteminations.
1992), future studies on the effect of suiphasalazine on pro-
tein kinase C activty may be helpful in delineating an addi-
tional mechanism for the observed nt of DDP
cytotoxcity by SS.
Our studies suggest that SS should be added to the long
list of agents which can enhance DDP cytotoxicity (Timmer-
Bosscha et al., 1992). The marked degre of enhancement of
DDP toxicity in the H-69 cell line at the lower concentrations
of SS is interesting. Based on SS pharmacokinetics in
humans, concentrations of SS up to 25pM can be achieved in
human plasma at relatively non-toxic doses of SS (Das &
Dubin, 1976). Furthermore, animal pharmacokinetic studie
of SS show that its concentrations in lung and connective
tissues are significntly higher Cm the range of 0.5 mM) than
in serum, and they can persist for prolonged periods after
bolus doses of SS (Hanngren et al., 1%3). These findings can
be helpful in designing chemotherapeutic regimens to test the
efficacy of SS in modulating the anti-cancer efficacy of DDP
in human malignancy, particularly lung cancer.
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